Back to School: How biopharma can reboot drug development. Access exclusive analysis here
INDICATION: Myotonic dystrophy type 1 (DM1)
Cell culture and mouse studies suggest inhibiting miR-23b
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury